- Home
- OPK vs QURE Comparison
OPK vs QURE Comparison
Compare OPK & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPK | QURE |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 1.1B |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPK | QURE |
|---|---|---|
| Price | $1.53 | $45.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $1.60 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 3.1M | 2.8M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,879,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | $4.24 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $8.73 |
| 52 Week High | $1.61 | $71.50 |
Technical Indicators
Market Signals| Indicator | OPK | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 69.05 | 67.91 |
| Support Level | $1.48 | $22.20 |
| Resistance Level | $1.58 | $60.70 |
| Average True Range (ATR) | 0.06 | 3.02 |
| MACD | 0.00 | 0.60 |
| Stochastic Oscillator | 67.97 | 79.72 |
Price Performance
Historical ComparisonAbout OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.